Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02348723 · ClinicalTrials.gov registry record · Phase 4
Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT)
A Phase 4 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 4
- Development phase
- 678
- Enrollment target
NCT02348723 is a Phase 4 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 678 participants.
The verdict
NCT02348723, a Phase 4 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 678 participants
- Enrollment target
Study Summary
The primary objective of this trial is to assess the safety of an uninterrupted dabigatran etexilate periprocedural anticoagulant regimen compared to an uninterrupted warfarin regimen in Non-Valvular Atrial Fibrillation (NVAF) patients undergoing Atrial Fibrillation (AF) ablation in a PROBE (Prospective, randomized, open label, blinded end point) active controlled study. Secondary objectives are to assess additional safety endpoints and efficacy in this clinical setting. It is not intended to assess confirmatory hypothesis, this is an exploratory study.
Interventions
- DRUG Warfarin
- DRUG Dabigatran Etexilate 150mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 678 participants |
| Start Date | 2015-04-28 |
| Est. Completion | 2016-11-14 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02348723
The ClinicalTrials.gov registry entry for NCT02348723 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 678 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Warfarin is the first listed.
NCT02348723 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02348723 about?
NCT02348723 is a clinical study titled "Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT)". The primary objective of this trial is to assess the safety of an uninterrupted dabigatran etexilate periprocedural anticoagulant regimen compared to an uninterrupted warfarin regimen in Non-Valvular Atrial Fibrillation (NVAF) patients undergoing Atrial Fibrillation (AF) ablation in a PROBE (Prospec...
What is the current status of trial NCT02348723?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 678 participants. The study started on 2015-04-28. Estimated completion is 2016-11-14.
What interventions are being tested in trial NCT02348723?
The interventions under investigation include: Warfarin (DRUG), Dabigatran Etexilate 150mg (DRUG).
Who is sponsoring clinical trial NCT02348723?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.